StockUS listing USPCRXNASDAQHealthcareDeep Value

Pacira BioSciences, Inc.(PCRX) Stock Analysis | Healthcare

USD --+0.00%
Reward52Moderate
Risk24Low
75%Data
Thin 2% profit margin
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.45Bn
Reward Ratingⓘ52 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ24 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on PCRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Pacira BioSciences, Inc.?

engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

AI Brief Pro

The brief on Pacira BioSciences, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Pacira BioSciences, Inc.?

engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.45B, and a P/E ratio of 103.7x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (52)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio103.7429
Beta0.252
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
425,000 shares
$628k
0
6-9months
27,261 shares
$158k
0
9-12months
534,336 shares
$852k
0

Openbook research

Articles mentioning PCRX

1